大北農(002385.SZ):控股子公司多產品獲批轉基因生物安全證書
格隆匯1月18日丨大北農(002385.SZ)公佈,2024年1月18日,農業農村部科學技術司發佈2023年農業轉基因生物安全證書批准清單(三),北京大北農科技集團股份有限公司控股子公司北京大北農生物技術有限公司(簡稱“大北農生物”)研發的抗蟲耐除草劑玉米、大豆等多個產品獲批,具體如下:
1、抗蟲耐除草劑大豆DBN8002獲批轉基因生物安全證書(進口);
2、抗蟲耐除草劑玉米DBN9936獲批轉基因生物安全證書(生產應用),為證書到期後續發;
3、抗蟲耐除草劑玉米DBN3601T、耐除草劑大豆DBN9004的有效區域由部分適宜生態區擴展到全國。
目前大北農生物第一代轉基因產品商業化進程國內領先,已獲得14個轉基因抗蟲耐除草劑玉米安全證書(生產應用)、3個轉基因抗蟲耐除草劑大豆安全證書(生產應用)及2個轉基因抗蟲耐除草劑大豆安全證書(進口)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.